KRAS and neoplasm: In KRAS G12C-mutant lung and colorectal cancers, combining KRAS G12C inhibitors adagrasib with sevenless homologue 1 (SOS1) inhibitors (BI-3406) or src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitors disrupts MRAS-driven receptor tyrosine kinase (RTK) feedback activation, enhancing anti-tumor efficacy and delaying resistance onset [248].